The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
Open accessAbstract
BACKGROUND: Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19. METHODS: Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig. RESULTS: 89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19. CONCLUSION: The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
WONG, C. K., LAM, C. W. K., WU, A. K. L., IP, W. K., LEE, N. L. S., CHAN, I. H. S., LIT, L. C. W., HUI, D. S. C., CHAN, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,274
Conti, P. (2020) · Journal of Biological Regulators and Homeostatic Agents · doi:10.23812/conti-e · Cited by 1,227
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13615-x · Cited by 1,158
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Lu, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.01020 · Cited by 1,133
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., & Wang, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25770 · Cited by 1,047
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Fu, Y., Cheng, Y., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00207-4 · Cited by 788
Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01461 · Cited by 775
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
Chen, L., Liu, H., Liu, W. Y., Liu, J., Liu, K., Shang, J., Deng, Y., & Wei, S. (2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0005 · Cited by 693
An interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome
Chen, I.-Y., Moriyama, M., Chang, M.-F., & Ichinohe, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00050 · Cited by 547
Risk of COVID-19 for patients with cancer
Xia, Y., Jin, R., Zhao, J., Li, W., & Shen, H. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30150-9 · Cited by 432
Risk of COVID-19 for patients with cancer
Wang, H., & Zhang, L. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30149-2 · Cited by 427
Zhao, Z. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05320-0 · Cited by 407
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
Wathelet, M. G., Orr, M., Frieman, M. B., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.00702-07 · Cited by 345
Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome
Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., Ye, L., Xu, S., Sun, R., Wang, Y., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.8.4410-4415.2004 · Cited by 338
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses.
Shen, L., Niu, J., Wang, C., Huang, B., Wang, W., Zhu, N., Deng, Y., Wang, H., Ye, F., Cen, S., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00023-19 · Cited by 319
Yoshikawa, T., Hill, T., Li, K., Peters, C. J., & Tseng, C.-T. K. (2009) · Journal of Virology · doi:10.1128/jvi.01792-08 · Cited by 293
Yamaya, M., Nishimura, H., Deng, X., Sugawara, M., Watanabe, O., Nomura, K., Shimotai, Y., Momma, H., Ichinose, M., & Kawase, T. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.005 · Cited by 251
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Lin, M.-H., Moses, D. C., Hsieh, C.-H., Cheng, S.-C., Chen, Y.-H., Sun, C.-Y., & Chou, C.-Y. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.015 · Cited by 250
Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.
Kritas, S. K. (2020) · JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS · doi:10.23812/20-editorial-kritas · Cited by 237
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Hart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Frieman, M. B., Holbrook, M. R., Jahrling, P. B., et al. (2014) · Journal of General Virology · doi:10.1099/vir.0.061911-0 · Cited by 211
Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus
Amici, C., Caro, A. D., Ciucci, A., Chiappa, L., Castilletti, C., Martella, V., Decaro, N., Buonavoglia, C., Capobianchi, M. R., & Santoro, M. G. (2006) · Antiviral Therapy · doi:10.1177/135965350601100803 · Cited by 203
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
Carbajo-Lozoya, J., Müller, M. A., Kallies, S., Thiel, V., Drosten, C., & von Brunn, A. (2012) · Virus Research · doi:10.1016/j.virusres.2012.02.002 · Cited by 201
Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection
Kim, E. S., Choe, P. G., Park, W. B., Oh, H. S., Kim, E. J., Nam, E. Y., Na, S. H., Kim, M., Song, K.-H., Bang, J. H., et al. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.11.1717 · Cited by 193
Cheng, K.-W., Cheng, S.-C., Chen, W.-Y., Lin, M.-H., Chuang, S.-J., Cheng, I.-H., Sun, C.-Y., & Chou, C.-Y. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2014.12.011 · Cited by 186
Milano, F., Campbell, A. P., Guthrie, K. A., Kuypers, J., Englund, J. A., Corey, L., & Boeckh, M. (2010) · Blood · doi:10.1182/blood-2009-09-244152 · Cited by 181
Ghamdi, M. A. A., Al-Ghamdi, K. M. G., Ghandoora, Y. M., Alzahrani, A., Salah, F., Alsulami, A., Bawayan, M. F., Vaidya, D. M., Perl, T. M., & Sood, G. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1492-4 · Cited by 159
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
Okabayashi, T., Kariwa, H., Yokota, S.-I., Iki, S., Indoh, T., Yokosawa, N., Takashima, I., Tsutsumi, H., & Fujii, N. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20556 · Cited by 158
Tseng, C.-T. K., Perrone, L. A., Zhu, H., Makino, S., & Peters, C. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7977 · Cited by 153
Zhang, X., Wu, K., Wang, D., Yue, X., Song, D., Zhu, Y., & Wu, J. (2007) · Virology · doi:10.1016/j.virol.2007.04.009 · Cited by 141 · cited 1×
“Following in vitro analysis, Yang et al [48] suggests the use of a combination therapy for SARS-CoV or MERS-CoV, wherein a tylophorine compound known to target transmissible gastroenteritis virus and a JAK2 inhibitor synergise to block the alternative dominant NF-κB activation mediated by JAK2.”
MethodCarbajo-Lozoya, J., Ma‐Lauer, Y., Malešević, M., Theuerkorn, M., Kahlert, V., Prell, E., von Brunn, B., Muth, D., Baumert, T. F., Drosten, C., et al. (2014) · Virus Research · doi:10.1016/j.virusres.2014.02.010 · Cited by 140
Li, Y., Chen, M., Cao, H., Zhu, Y., Zheng, J., & Zhou, H. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2012.10.008 · Cited by 140
Day, C. W., Baric, R. S., Cai, S. X., Frieman, M. B., Kumaki, Y., Morrey, J. D., Smee, D. F., & Barnard, D. L. (2009) · Virology · doi:10.1016/j.virol.2009.09.023 · Cited by 139
Ma, Y., Wang, C., Xue, M., Fu, F., Zhang, X., Li, L., Yin, L., Xu, W., Feng, L., & Liu, P. (2018) · Journal of Virology · doi:10.1128/jvi.00728-18 · Cited by 115
Balzarini, J. M. (2007) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020701800101 · Cited by 109
Barnard, D. L., Day, C. W., Bailey, K. W., Heiner, M., Montgomery, R. A., Lauridsen, L., Winslow, S. G., Hoopes, J. D., Li, J. K.-K., Lee, J., et al. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.03.001 · Cited by 107
Yang, C., Lee, Y., Kang, I., Barnard, D. L., Jan, J., Lin, D., Huang, C.-W., Yeh, T., Chao, Y., & Lee, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.08.009 · Cited by 106
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant
Hijano, D. R., Marón, G. M., & Hayden, R. T. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03097 · Cited by 106
MERS CoV Infection in Two Renal Transplant Recipients: Case Report
AlGhamdi, M., Mushtaq, F., Awn, N., & Shalhoub, S. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13085 · Cited by 102
The management of coronavirus infections with particular reference to SARS
Wong, S. S. Y., & Yuen, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn243 · Cited by 101
A review of treatment modalities for Middle East Respiratory Syndrome
Mo, Y., & Fisher, D. A. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw338 · Cited by 99
Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
Nilsson, A., Edner, N., Albert, J., & Ternhag, A. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1729403 · Cited by 99
Recent Developments in Anti-Severe Acute Respiratory Syndrome Coronavirus Chemotherapy
Barnard, D. L., & Kumaki, Y. (2011) · Future Virology · doi:10.2217/fvl.11.33 · Cited by 98
Severe acute respiratory syndrome: clinical and laboratory manifestations.
Lam, C. W. K., Chan, M. H. M., & Wong, C. K. (2004) · PubMed Central · Cited by 91
Inflammatory Cytokine Profile in Children With Severe Acute Respiratory Syndrome
Ng, P. C., Lam, C. W. K., Li, A. M., Wong, C. K., Cheng, F. W. T., Leung, T. F., Hon, E. K. L., Chan, I. H. S., Li, C. K., Fung, K. S. C., et al. (2004) · PEDIATRICS · doi:10.1542/peds.113.1.e7 · Cited by 90
Ogimi, C., Waghmare, A., Kuypers, J. M., Xie, H., Yeung, C. C. S., Leisenring, W. M., Seo, S., Choi, S., Jerome, K. R., Englund, J. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix160 · Cited by 84
Wang, W.-K., Chen, S.-Y., Liu, I.-J., Kao, C., Chen, H.-L., Chiang, B., Wang, J.-T., Sheng, W.-H., Hsueh, P., Yang, C.-F., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423808 · Cited by 80
Chen, X., Chou, C., & Chang, G. (2009) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020901900402 · Cited by 79
SARS Immunity and Vaccination.
Minsheng, Z. (2004) · PubMed · Cited by 70
Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
Jin, H., Xiao, C., Chen, Z., Kang, Y., Ma, Y., Zhu, K., Xie, Q., Tu, Y.-X., Yu, Y., & Wang, B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.048 · Cited by 69
Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer
Folz, R. J., & Elkordy, M. (1999) · CHEST Journal · doi:10.1378/chest.115.3.901 · Cited by 68
Yang, C., Lee, Y., Hsu, H., Shih, C., Chao, Y., Chang, H., & Lee, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-04203-9 · Cited by 66
Liao, Y., Wang, X., Huang, M., Tam, J. P., & Liu, D. X. (2011) · Virology · doi:10.1016/j.virol.2011.09.003 · Cited by 65
Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus
Zalinger, Z. B., Elliott, R., & Weiss, S. R. (2017) · Journal of NeuroVirology · doi:10.1007/s13365-017-0574-4 · Cited by 60
Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy
Ghosh, A. K., Xi, K., Johnson, M. E., Baker, S. C., & Mesecar, A. D. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41011-3 · Cited by 58
Zhang, X., Alekseev, K. P., Jung, K., Vlasova, A. N., Hadya, N., & Saif, L. J. (2008) · Journal of Virology · doi:10.1128/jvi.02190-07 · Cited by 56
Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Al‐Tawfiq, J. A., & Memish, Z. A. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1271712 · Cited by 53
Sheng, W., Chiang, B., Chang, S., Ho, H.-N., Wang, J., Chen, Y., Hsiao, C.-H., Hseuh, P.-R., Chie, W., & Yang, P. (2005) · PubMed · Cited by 51
TNF-α inhibition for potential therapeutic modulation of SARS coronavirus infection
Tobinick, E. L. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002757 · Cited by 48
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
Rabaan, A. A., Al-Ahmed, S. H., Bazzi, A. M., & Alhani, H. M. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000565 · Cited by 45
Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
Benites, E. C. A., Cabrini, D. P., Silva, A. C. B., Silva, J. C., Catalan, D. T., Berezin, E. N., Cardoso, M. R. A., & Passos, S. D. (2014) · Jornal de Pediatria · doi:10.1016/j.jped.2014.01.006 · Cited by 41
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Mahmud-Al-Rafat, A., Majumder, A., Rahman, K. M. T., Hasan, A. M. M., Islam, K. M. D., Taylor-Robinson, A. W., & Billah, M. M. (2019) · Cytokine · doi:10.1016/j.cyto.2018.12.008 · Cited by 37
Cinatl, J. J., Michaelis, M., Morgenstern, B., & Doerr, H. W. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.15.2.323 · Cited by 34
Miura, T. A., Wang, J., Holmes, K. V., & Mason, R. J. (2007) · Virology · doi:10.1016/j.virol.2007.07.030 · Cited by 33
Ishii, K., Hasegawa, H., Nagata, N., Ami, Y., Fukushi, S., Taguchi, F., & Tsunetsugu‐Yokota, Y. (2008) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00097.x · Cited by 20
LaFemina, R. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03406-14 · Cited by 8
[Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome].
Wang, C., & Pang, B. (2003) · PubMed · Cited by 7
Cited by
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Zimmermann, P., & Curtis, N. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
A Review of Persistent Post-COVID Syndrome (PPCS)
Oronsky, B., Larson, C., Hammond, T. C., Oronsky, A., Kesari, S., Lybeck, M., & Reid, T. R. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08848-3 · Cited by 422
COVID-19 and the Immune System
PACES, J., STRIZOVA, Z., SMRZ, D., & CERNY, J. (2020) · Physiological Research · doi:10.33549/physiolres.934492 · Cited by 340
Metadata
- Authors
- Russell, B., Moss, C., George, G., Santaolalla, A., Cope, A., Papa, S., & Van Hemelrijck, M.
- Venue
- ecancermedicalscience
- Publisher
- Ecancer Global Foundation
- Published
- 2020-03-27
- Volume
- 14
- Pages
- 1022-1022
- ISSN
- 1754-6605 (ISSN-L)
- OpenAlex
- W3013893688
- Cited by
- 439
- References
- 76
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.